Completed PHASE4 INTERVENTIONAL 2-arm NCT00140530

Nonpolymer- and Polymer-Based Drug-Eluting Stents for Restenosis (ISAR-TEST-1)

A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1)

Sponsor: Bayerische Forschungsstiftung Muenchen

Conditions Coronary Disease

Interventions Paclitaxel-eluting stent (Taxus) Rapamycin-eluting stent

Updated 6 times since 2017 Last updated: Jan 10, 2008 Started: Mar 31, 2004 Completion: Jun 30, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Coronary Disease, this trial is completed. The trial is conducted by Bayerische Forschungsstiftung Muenchen and has accumulated 6 data snapshots since 2004. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayerische Forschungsstiftung Muenchen
Deutsches Herzzentrum Muenchen

Data source: Deutsches Herzzentrum Muenchen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Munich, Germany